Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,535 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
Regulatory Filings
2026-06-08 Danish
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
Transaction in Own Shares Classification · 97% confidence The document is a company announcement detailing transactions executed under its share buy-back program, including number of shares repurchased, prices, accumulated totals, and treasury share holdings. This matches ‘‘Transaction in Own Shares’’ (share repurchase) filings.
2026-06-08 English
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Share Issue/Capital Change Classification · 90% confidence The document is a company announcement detailing the issuance of 53,183 new shares due to the exercise of employee warrants and the resulting increase in share capital, including nominal values, registration details, and admission to trading. This constitutes a capital change (share issue) rather than an earnings report, management change, or financial report. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-06-08 English
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in p
Regulatory Filings Classification · 90% confidence The document is a corporate press announcement of positive Phase III clinical trial results. It contains no financial statements, regulatory form references, or shareholder voting information, nor does it announce an issuer report publication. It is a general corporate announcement and does not fit any specific financial filing category, so it falls under the fallback category Regulatory Filings (RNS).
2026-06-07 English
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
Regulatory Filings
2026-06-01 Danish
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
Transaction in Own Shares Classification · 99% confidence The document is a company announcement detailing weekly transactions under its share buy-back program, including numbers of shares repurchased and related data. This directly corresponds to a report of the company buying back its own shares. Such reports fall under the 'Transaction in Own Shares' category (Code: POS).
2026-06-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.